Healthcare Industry Media Coverage2017-09-13T20:18:16+00:00

Media Coverage

Lupus Clinical Trials May Not Be Representative of Real-World Population, Report Suggests

From: Lupus News Today By: Iqra Mumal Patients participating in Phase 3 clinical trials testing new therapies for systemic lupus erythematosus (SLE) are not necessarily representative of real-world patient populations, according to a new report. Even if the therapies being investigated reach the market, real-world experiences may differ significantly from trial results because many lupus patients are not eligible to participate in studies due to exclusion criteria, the report says....(read more).

August 1, 2018|

Ocrevus Proves Mettle in Real-World PPMS – Adverse events from ongoing study in line with major trial results

From: MedPage Today By: Salynn Boyles, Contributing Writer, MedPAge Today NASHVILLE -- Ocrelizumab (Ocrevus), the first and only FDA-approved disease-modifying therapy (DMT) to treat primary progressive multiple sclerosis (PPMS), has lived up to its hype, according to the CEO of the Consortium of Multiple Sclerosis Centers (CMSC). "Ocrelizumab has really changed the landscape for patients who haven't had many therapeutic options in the past. I do think that, so far at least, it has lived up to the hype," June Halper, MSN, told MedPage Today. Ocrelizumab is a humanized, monoclonal antibody that targets CD20+ B cells. FDA approval in 2017 [...]

June 7, 2018|

Ustekinumab Makes Inroads in Crohn’s Disease – Docs opt for psoriasis drug when anti-TNF agents fail

From: MedPage Today Byy: Ed Susman, Contribution Writer, MedPAge Today LAS VEGAS -- TNF inhibitors remain the predominant treatment in Crohn's disease, but ustekinumab (Stelara) has been quickly adopted by clinicians, accounting for about one in five recently switched patients, researchers reported here. The agent received FDA approval in 2016 for the treatment of moderately to severely active Crohn's disease in adults who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a TNF blocker, or who failed or were intolerant to treatment with one or more TNF blockers...(read more).

January 22, 2018|

Cosentyx Plateaus as Non-TNF Agents Prepare to Dominate in Psoriatic Arthritis

From: Specialty Pharma Time By: Lauren Santye Although there are a growing number of rheumatologists in the United States who report the use of Cosentyx to treat psoriatic arthritis (PsA), the increasing user base has failed to translate into overall increases in biologic share, according to market research company Spherix Global Insights. The plateau of Cosentyx is partially fueled by pipeline PsA agents, which offer patients more options for non-TNF treatments, including Orcenia, Xeljanz, and Taltz, according to a press release....(read more).

August 17, 2017|

Early US dermatologist’s views of Tremfya leave ground to be covered

From: The Pharma Letter Early US dermatologist's views of Tremfya leave ground to be covered At two weeks post launch, only half of the surveyed US dermatologists (n=104) were aware of Tremfya's (guselkumab) approval when aided. The drug was approved by the US Food and Drug Administration on July 13 as a treatment for moderate to severe plaque psoriasis...(read more)

August 11, 2017|